Abstract
Restless legs syndrome (RLS), formally identified and described by Ekbom in the 1940s, is a common clinical disorder, characterized by an overwhelming urge to move the legs, often accompanied by uncomfortable and unpleasant sensations. This impulse can also be present in the upper limbs or other parts of the body. Well recognized in the adult population, the symptoms associated with this condition have commonly been reported to originate in childhood. However, identifying prospectively children suffering from RLS is still a challenging issue. Iron deficiency has been recognized as a feature frequently associated with RLS. Some authors also make a connection with the deficiency, RLS and other common problems encountered in children, such as attention deficit disorder with hyperactivity (ADHD). Linkage to different chromosomal loci has been achieved in recent genetic studies of large kindred, as well as identification of specific genes. Therapeutic considerations in children range from providing sound sleep hygiene to intervening pharmacologically. In that regard, use of iron supplements, dopaminergic stimulation, anticonvulsants, opiates, and benzodiazepines will be assessed along with newer options, such as rotigotine and gabapentin enacarbil. Considerations specific to childhood do apply, as no pharmacological therapy for restless legs syndrome have been approved by the Federal Drug Administration (FDA) in individuals of the pediatric age group.
Keywords: Restless legs syndrome, RLS, dopamine agonist, augmentation, ferritin, pediatric, genetics, treatment, dopamine, bruise, orthopedic, autosomal, fibromyalgia, myelopathy, tyrosine, sclerosis, thyroid, radiculopathy, sickle cell, tendon strain
Current Pharmaceutical Design
Title: Restless Legs Syndrome in Children: A Review and Update on Pharmacological Options
Volume: 17 Issue: 15
Author(s): Eric Frenette
Affiliation:
Keywords: Restless legs syndrome, RLS, dopamine agonist, augmentation, ferritin, pediatric, genetics, treatment, dopamine, bruise, orthopedic, autosomal, fibromyalgia, myelopathy, tyrosine, sclerosis, thyroid, radiculopathy, sickle cell, tendon strain
Abstract: Restless legs syndrome (RLS), formally identified and described by Ekbom in the 1940s, is a common clinical disorder, characterized by an overwhelming urge to move the legs, often accompanied by uncomfortable and unpleasant sensations. This impulse can also be present in the upper limbs or other parts of the body. Well recognized in the adult population, the symptoms associated with this condition have commonly been reported to originate in childhood. However, identifying prospectively children suffering from RLS is still a challenging issue. Iron deficiency has been recognized as a feature frequently associated with RLS. Some authors also make a connection with the deficiency, RLS and other common problems encountered in children, such as attention deficit disorder with hyperactivity (ADHD). Linkage to different chromosomal loci has been achieved in recent genetic studies of large kindred, as well as identification of specific genes. Therapeutic considerations in children range from providing sound sleep hygiene to intervening pharmacologically. In that regard, use of iron supplements, dopaminergic stimulation, anticonvulsants, opiates, and benzodiazepines will be assessed along with newer options, such as rotigotine and gabapentin enacarbil. Considerations specific to childhood do apply, as no pharmacological therapy for restless legs syndrome have been approved by the Federal Drug Administration (FDA) in individuals of the pediatric age group.
Export Options
About this article
Cite this article as:
Frenette Eric, Restless Legs Syndrome in Children: A Review and Update on Pharmacological Options, Current Pharmaceutical Design 2011; 17 (15) . https://dx.doi.org/10.2174/138161211796197142
DOI https://dx.doi.org/10.2174/138161211796197142 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
β-Barrel Membrane Bacterial Proteins: Structure, Function, Assembly and Interaction with Lipids
Current Protein & Peptide Science Role of Wnt Signaling in Tissue Fibrosis, Lessons from Skeletal Muscle and Kidney
Current Molecular Medicine Protein-Protein Interface Analysis and Hot Spots Identification for Chemical Ligand Design
Current Pharmaceutical Design Mechanisms of Drug Induced QT Interval Prolongation
Current Drug Safety Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System
Current Medicinal Chemistry Withdrawal Notice: A Panoramic View on the Phytochemical, Nutritional and Therapeutic value of Ziziphus mauritiana Lam.: A Comprehensive Review
Mini-Reviews in Medicinal Chemistry Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson’s Disease: Defining the Preclinical, Clinical and Toxicity Issues
Current Drug Delivery Thrombolysis in Ischemic Stroke: Focus on New Treatment Strategies
Recent Patents on Cardiovascular Drug Discovery Effects of Acute and Chronic Treatment of Novel Psychotropic Drug, 8- (Trifluoromethyl)-1, 2, 3, 4, 5-benzopentathiepin-6-amine Hydrochloride (TC-2153), on the Behavior of Zebrafish (Danio Rerio): A Comparison with Fluoxetine
Letters in Drug Design & Discovery 20 Years of Lipid Nanoparticles (SLN & NLC): Present State of Development & Industrial Applications
Current Drug Discovery Technologies Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design Linkage of Stress with Neuromuscular Disorders
CNS & Neurological Disorders - Drug Targets Potential Therapeutic Benefits of Maintaining Mitochondrial Health in Peripheral Neuropathies
Current Neuropharmacology Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) GqPCR-mediated Signalling in the Spotlight: From Visualization Towards Dissection and Quantification
Current Pharmaceutical Biotechnology Transglutaminase Inhibition as a Possible Therapeutical Approach to Protect Cells from Death in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Senescence of the Brain: Focus on Cognitive Kinases
Current Pharmaceutical Design Gene Therapy for Parkinsons Disease: Progress and Challenges
Current Gene Therapy Osmoadaptation of Mammalian Cells - An Orchestrated Network of Protective Genes
Current Genomics Applications of Positron Emission Tomography in Neuropsychiatric Pharmaceutical Drug Development
Current Radiopharmaceuticals